These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18205839)

  • 1. Strategies to optimize the use of targeted agents for tumor therapy.
    Becker JC; Ugurel S; Schrama D
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):281-5. PubMed ID: 18205839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for optimizing combinations of molecularly targeted anticancer agents.
    Dancey JE; Chen HX
    Nat Rev Drug Discov; 2006 Aug; 5(8):649-59. PubMed ID: 16883303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoscale delivery systems for multiple drug combinations in cancer.
    Cao Y; Wang B; Lou D; Wang Y; Hao S; Zhang L
    Future Oncol; 2011 Nov; 7(11):1347-57. PubMed ID: 22044207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
    Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
    Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slaying RAS with a synthetic lethal weapon.
    Bommi-Reddy A; Kaelin WG
    Cell Res; 2010 Feb; 20(2):119-21. PubMed ID: 20118966
    [No Abstract]   [Full Text] [Related]  

  • 8. Multitargeted therapy: can promiscuity be praised in an era of political correctness?
    Jimeno A; Hidalgo M
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):150-8. PubMed ID: 16843676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
    Blum R; Kloog Y
    Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy.
    Wright JJ
    Clin Cancer Res; 2010 Aug; 16(16):4094-104. PubMed ID: 20682705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer trial assesses clinical benefit of gene-targeted treatment.
    Katsnelson A
    Nat Biotechnol; 2014 Apr; 32(4):306. PubMed ID: 24714466
    [No Abstract]   [Full Text] [Related]  

  • 18. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
    Eberle J; Kurbanov BM; Hossini AM; Trefzer U; Fecker LF
    Drug Resist Updat; 2007 Dec; 10(6):218-34. PubMed ID: 18054518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reanalysis of cancer drugs: old drugs, new tricks.
    Vande Woude GF; Kelloff GJ; Ruddon RW; Koo HM; Sigman CC; Barrett JC; Day RW; Dicker AP; Kerbel RS; Parkinson DR; Slichenmyer WJ
    Clin Cancer Res; 2004 Jun; 10(11):3897-907. PubMed ID: 15173099
    [No Abstract]   [Full Text] [Related]  

  • 20. Polymeric micelles drug delivery system in oncology.
    Gong J; Chen M; Zheng Y; Wang S; Wang Y
    J Control Release; 2012 May; 159(3):312-23. PubMed ID: 22285551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.